The campaign aims to raise awareness of a condition that affects an estimated 24 million adults in the US, many of whom remain undiagnosed
The move marks one of the most significant coverage expansions yet in obesity care, bringing FDA-approved treatment options further into mainstream insurance plans rather than out-of-pocket reach
The once-daily oral medication is approved for adults with obesity or overweight who have weight-related medical conditions
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
Patients can now get the starting 2.5 mg dose for $299 per month
Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
